Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

In DMD, Summit Falls Well Short Of Peak It Hoped For

Executive Summary

Summit’s utrophin modulator, ezutromid, posted intriguing interim data in January, but failed to meet the primary and all secondary endpoints in a Phase II study. The UK firm discontinued development of ezutromid and will now focus on novel antibiotic candidates.

You may also be interested in...



Summit's Lead Antimicrobial Fails Pivotal Study, May Spark Therapeutic Shift

Ridinilazole fell short of significance in a late-stage trial, with some analysts now anticipating the company will alter its therapeutic strategy entirely.

Roche Discontinues Duchenne Hope At Interim Analysis

Roche is to discontinue its RG6206 clinical development program in Duchenne muscular dystrophy after an interim analysis of the Phase II/III SPITFIRE study indicates the compound would be “highly unlikely” to show a clinical benefit.

Summit Looking To Secure Superiority Claim For Ridinilazole Over Vancomycin In C. Diff

Company’s Phase III program is attempting to replicate Phase II efficacy data showing superiority for curing Clostridium difficile infections and preventing recurrence, while also compiling health economics data.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC123326

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel